Quantcast
Last updated on April 18, 2014 at 7:29 EDT

Phylogica and Pepscan Enter Collaboration to Optimise Therapeutic Phylomer(R) Drug Candidates

May 10, 2011

PERTH, Australia and LELYSTAD, The Netherlands, May 10, 2011 /PRNewswire/
– Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug
discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm
focusing on protein mimicry technology, today announce that they have entered
a Research Collaboration and Option Agreement to evaluate the combination of
their complementary peptide technologies for drug discovery. Under the terms
of the agreement, Pepscan using its CLIPS technology will work with Phylogica
to optimise novel therapeutic Phylomer drug candidates against CD40-ligand
for the treatment of rheumatoid arthritis, autoimmune diseases and
inflammatory disorders. Phylogica will also have an option to expand the
collaboration to include an undisclosed number of other disease-associated
targets. Financial details were not disclosed

Phylogica’s CEO, Dr Paul Watt, said: “We are excited to be working with
Pepscan, which has world-class technology for improving the activity and
stability of therapeutic peptides. We strongly believe that the combination
of Pepscan’s CLIPS technology with our potent Phylomer peptides will further
enhance our ability to generate breakthrough drug candidates against
difficult-to-treat diseases.”

Dr Wim Mol, CEO of Pepscan, said: “We jointly recognise the perfect match
of our combined technologies – Phylogica providing truly innovative peptide
leads, and Pepscan applying its state-of-the-art CLIPS technology for peptide
lead optimisation. We therefore believe that this agreement only forms the
start of a promising and productive relationship between our two companies.”

About Phylogica

Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth,
Australia
, and Oxford, UK, with a world-class drug discovery platform
harnessing the rich biodiversity of nature to discover novel peptide
therapeutics. The Company was incorporated in 2001 as a spin out from the
Telethon Institute for Child Health Research (Perth, Australia) and the Fox
Chase Cancer Centre (Philadelphia, USA). The Company’s drug discovery
platform is based on its proprietary Phylomer(R) libraries of natural
peptides, which have been optimised by evolutionary selection to have stable
drug-like structures. Phylogica offers fully integrated drug discovery
services to the pharmaceutical industry utilising its Phylomer(R) libraries
and proprietary screening technologies. Its current partners include Roche,
MedImmune (the worldwide biologics unit of AstraZeneca) and Pfizer.

About Phylomer(R) Peptides

Phylomer peptides are derived from biodiverse natural sequences, which
have been selected by evolution to form stable structures, which can bind
tightly, and specifically to disease associated target proteins, both inside
and outside cells. Suitable targets for blockade by Phylomers include protein
interactions that promote multiple diseases, such as infectious diseases,
cancer, autoimmunity and heart disease. Phylomer peptides can have drug-like
properties, including specificity, potency and thermal stability, and are
capable of being produced by synthetic or recombinant manufacturing
processes. Phylomer peptides are also readily formulated for administration
by a number of means, including parenteral or intranasal delivery approaches.

About Pepscan

Pepscan Therapeutics is a privately held biopharmaceutical company based
in Lelystad, The Netherlands. Pepscan is applying its proprietary high
throughput CLIPS protein mimicking technology for the development of novel
constrained therapeutic peptides and immunogens. Besides its pipeline of
therapeutic peptides and anti-GPCR monoclonal antibody products, Pepscan has
various ongoing collaborations with leading pharmaceutical and biotech
companies to develop novel therapeutics based on the proprietary CLIPS
technology platform.

About CLIPS

CLIPS (Chemical LInkage of Peptides onto Scaffolds) is a technology to
present one or more peptides in a structurally constrained configuration.
These molecules behave as functional mimics of structurally complex protein
domains. CLIPS therapeutic peptides have been shown to exert improved
activity and stability. CLIPS peptides are also used as superior immunogens
for antibody generation against disease relevant protein targets. This is
especially valuable in the case of proteins that are inaccessible as
recombinant proteins, such as GPCRs.

SOURCE Pepscan Therapeutics


Source: newswire